Usefulness of Aspiration of Pulmonary Emboli and Prolonged Local Thrombolysis to Treat Pulmonary Embolism  by Cuculi, F. et al.
Abstracts
Gregory L. Moneta, MD, Section EditorAssociation Between Surgical Care Improvement Program Venous
Thromboembolism Measures and Postoperative Events
Altom LK, Deierhoi RJ, Grams J, et al. Am J Surg 2012;204:591-7.
Conclusion: There is no association between rates of venous throm-
boembolism (VTE) and adherence to the Surgical Care Improvement
Program (SCIP) implemented measures to reduce VTE.
Summary: SCIP was implemented by the Centers for Medicare and
Medicaid Services (CMS) in 2006. The goal of SCIP is to reduce surgical
complications, surgical site infections, adverse cardiac events, and thrombo-
embolism by 25%. SCIP is a core measure collected by the Joint Commis-
sion. In-hospital adherence to SCIP measures is reported publicly. Deep
venous thrombosis and pulmonary embolism are known to be potentially
signiﬁcant causes of postoperative morbidity and mortality. SCIP intro-
duced two VTE prophylactic measures for surgical procedures as reﬂected
in guidelines from the American College of Chest Physicians. SCIP-VTE-
1 measures whether VTE prophylaxis was ordered, and SCIP-VTE-2
measures whether prophylaxis was received; both #24 hours of surgery.
This study sought to determine the rates of adherence to SCIP-VTE guide-
lines, to identify factors for nonadherence, and to analyze relationships
between SCIP guideline adherence and VTE events in the context of other
patient and procedure factors. This was a retrospective cohort study of data
from the VA Surgical Quality Improvement Program from 2006 to 2009.
There were 30,531 surgeries analyzed. Patient demographics, comorbid-
ities, and surgical characteristics associated with VTE were summarized.
VTE rates were compared by SCIP-VTE adherence. VTE was modeled
by adherence to SCIP and adjusting for multiple associated factors using
multivariable logistic regression. Of the 30,531 surgeries evaluated, 89.9%
adhered to SCIP-VTE, and 1.4% experienced VTE. Obesity, smoking, func-
tional status, weight loss, emergency status, age >64 years, and surgical time
were identiﬁed by logistic regression to be associated with VTE. SCIP-VTE
adherence was not associated with VTE (1.4% vs 1.33%; P ¼ .3). The lack of
association of SCIP-VTE with VTE remained even after adjustment for
compounding variables.
Comment: Most prior analyses of SCIP measures have focused on
surgical site infection. These analyses have not provided convincing evidence
that adherence to SCIP surgical site infection measures reduces the rate of
surgical site infections. Similarly, this study suggests compliance with SCIP-
VTE prevention measures has no measurable association with events that
are intended to be prevented by adherence to the SCIP-VTE measures.
SCIP-VTE measures may be ineffective or too limited to compensate for
the large variation and complexity of patient and surgical factors contrib-
uting to VTE. No one will argue that reduction of surgical associated
VTE is a desirable goal. However, the SCIP regulations should be consid-
ered for elimination or modiﬁcation if they are not found to produce their
intended results.Renal Sympathetic Denervation for Treatment of Drug-Resistant
Hypertension: One-Year Results From the Symplicity HTN-2
Randomized Controlled Trial
Esler MD, Krum H, Schlaich M, and the Symplicity HTN-2 Investigators.
Circulation 2012;126:2976-82.
Conclusion: Renal denervation provides safe and sustained reduction
of blood pressure to 1 year.
Summary: The number of adults with hypertension is expected to
grow to >1.5 billion worldwide by 2025 (Kearney PM et al, Lancet
2005;365:217-23). There is a subset of patients with particularly difﬁcult
to control hypertension who, despite adherence to three or more drugs,
continue to have uncontrolled or resistant hypertension (Mahfoud F et al,
Deutsches Arzteblatt Internation 2011;108:725-31). Resistant hyperten-
sion prevalence in the United States ranges from 13% to 30% (Persell SD
et al, Hypertension 2011;57:1076-80). There is activation of the renal
sympathetic system in patients with essential hypertension. Efferent sympa-
thetic outﬂow to the kidneys results in elevation of blood pressure via release
of renin. In addition, afferent nerve signaling from the kidneys with renal
injury also stimulates sympathetic outﬂow from the central nervous system.
There have been preclinical studies of renal denervation in animal models of
hypertension that provide direct evidence of blood pressure loweringthrough renal denervation. This suggests a signiﬁcant role of the sympa-
thetic nervous system of the kidney in the pathogenesis of hypertension
(DiBona GF et al, Physiol Rev 1997;77:75-197). Renal denervation can
be accomplished with the application of radiofrequency energy in short
bursts along the length of the main renal arteries. The result is ablation of
renal nerves that lay within and just beyond the adventitial tissue of the renal
arteries. The Symplicity HTN-1 Trial, along with a registry of patients with
resistant hypertension treated by renal denervation, have demonstrated
reductions in ofﬁce-based blood pressure, apparently without serious
adverse events (Investigators Symplicity HTN-1, Hypertension
2011;57:911-7). Symplicity HTN-2 is a multicenter randomized trial that
previously demonstrated catheter-based renal denervation provided signiﬁ-
cant lowering of blood pressure in treatment-resistant patients at 6 months
after the procedure compared with control, medication-only patients. In this
report, the authors present longer follow-up and include 6-month crossover
results of Symplicity HTN-2. Eligible patients were taking three or more
antihypertensive medicines and had a baseline systolic blood pressure
$160 mm Hg ($150 mm Hg for type 2 diabetic patients). After the
6-month end points were met, renal denervation was permitted in control
patients. Here the authors present 1-year results of 47 patients randomized
to immediate renal denervation and 6-month postprocedure results for
crossover patients. At 12 months after the procedure, the mean fall in ofﬁce
systolic blood pressure in the initial renal denervation group (28.1 mm
Hg; 95% conﬁdence interval, 35.4 to 20.7; P < .001) was similar to the
6-month fall (31.7 mm Hg; 95% conﬁdence interval, 38 to 25.0;
P ¼ .16 compared to the fall at 6 months). The mean systolic blood pressure
of the crossover group 6 months after the procedure was signiﬁcantly lower,
from 190 6 19.6 to 166.3 6 24.7 mm Hg (change, 23.7 6 27.5;
P < .001). There was one renal artery dissection associated with guide cath-
eter insertion in the crossover group and one hypotensive episode that
resolved with medication adjustment.
Comment: The mechanisms of essential hypertension are slowly
being unraveled. It appears renal sympathetic nerve activation has a role
in the production of essential hypertension and that denervation of the
kidney, with catheter based techniques, has the potential to interrupt renal
afferent and efferent nerves, resulting in decreased sympathetic outﬂow to
the kidneys, reduced renin release, decreased sodium retention, increased
renal blood ﬂow, and lower blood pressure. Thus far, there has not been
animal or clinical evidence that use of the Simplicity catheter to denervate
the kidneys results in sustained damage to the renal arteries. There has
also been no documentation of adverse effects on renal function at 6 and
12 months after renal denervation. Renal denervation appears to have the
potential to provide safe and effective adjunctive treatment for drug-resis-
tant hypertensive patients.Usefulness of Aspiration of Pulmonary Emboli and Prolonged Local
Thrombolysis to Treat Pulmonary Embolism
Cuculi F, Kobza R, Bergner M, et al. Am J Cardiol 2012;110:1841-5.
Conclusion: In patients with pulmonary embolism (PE), manual aspi-
ration and application of prolonged thrombolysis is feasible and safe, with
signiﬁcant improvement in pulmonary artery pressures.
Summary: A catheter-based intervention for signiﬁcant PE can be an
alternative to systemic thrombolysis or surgical embolectomy. There are
multiple catheter-based techniques that can be used in the treatment of
PE, including thrombus fragmentation, rheolytic thrombectomy, suction
thrombectomy, and rotational thrombectomy. In this report, the authors
describe a new pharmacomechanical approach to catheter-based treatment
of PE using prolonged infusion of urokinase directly into the pulmonary
arteries. Manual aspiration of thrombus using guide catheters was followed
by introduction of thrombolysis catheters and a local bolus of urokinase.
Lysis catheters were left in place and repeat pulmonary artery angiography
and right-side cardiac catheterization performed 3 days later. Sixty-three
patients with a mean age of 60 6 15 years were treated over 8 years. The
PE was massive in 17 patients (27%) and submassive in 46 (73%). Mean
pulmonary artery (PA) pressure was 35 6 10 mm Hg, and 54% had central
bilateral PE. Five patients died, one before, one during, and three after
intervention. Nine patients (14%) had major bleeding episodes. Bleeding
was not responsible for any fatal outcome. After 3.3 6 1.0 days, 49 of 581171
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of thrombotic burden by >90%, and in 14 (29%) the reduction was 50% to
90%. PA pressures fell from 33 6 8 to 21 6 7 mm Hg, (P < .001).
Decreased PA pressure was not dependent on thrombus reduction.
Comment: The authors’ technique of combined catheter-based
mechanical and pharmacologic treatment of large PE was reasonably
safe, with major bleeding rates of 14% compared with 9% in a recent
meta-analysis of systemic thrombolysis only (Kearon C et al, Chest
2012;141:e419-4S). The data, however, are not completely internally
consistent, in that physiologic improvement in PA pressure did not directly
correlate with the reduction of thrombotic burden. Although it is known
that imaging and physiology do not necessarily correlate precisely in other
vascular beds, the authors’ observations suggest there may be more than
just thrombotic burden contributing to the elevated PA pressures in patients
with PE.Complete Replacement of Open Repair for Ruptured Abdominal
Aortic Aneurysms by Endovascular Aneurysm Repair. A Two-Center
14-Year Experience
Mayer D, Aeschbacher S, Pfammatter T, et al. Ann Surg 2012;256:688-96.
Conclusion: An endovascular aneurysm repair (EVAR)-only
approach to treatment of patients with ruptured abdominal aortic aneurysm
(rAAA) allows EVAR treatment of virtually all rAAA with low mortality and
turndown rates.
Summary: There is controversy regarding the beneﬁt of EVAR in
treatment of patients with rAAA. It has been suggested that improved
mortality rates of rAAA in patients treated with EVAR does not necessarily
reﬂect superiority of the endovascular procedure over the open procedure.
It has been argued that patients with rAAA suitable for EVAR, who are
treated with an open operation, have lower mortality than patients not suit-
able for EVAR treated with open surgery. In addition, it is argued that
patients treated with open surgery are hemodynamically less stable than
those treated with EVAR. The argument, therefore, is that patients treated
with EVAR for rAAA do better as a consequence of being more stable and
anatomically better-risk patients. The authors’ favorable experience with
EVAR for rAAA in the past led them to institute a policy of try-to-treat
rAAA with EVAR whenever possible. In essence, this meant introducing
adjunctive techniques, such as chimney procedures and iliac debranching
as well as coiling of the aneurysm sac, to treatment of rAAA patients with
EVAR. Since May 2009, all rAAA, except one, in the authors’ institutions
have been treated by EVAR. The 30-day mortality was 24%. During the
authors’ EVAR-only protocol for rAAA, only three patients (4%) were
turned down for surgical treatment. From January 1998 until April 2009,
the authors previously used an EVAR/open policy using an “EVAR-when-
ever-possible” approach. In patients in whom abdominal decompression
with laparotomy was performed, no decrease in mortality was observed
for EVAR compared with open repair (unadjusted odds ratio, 1.1; 95%
conﬁdence interval [CI], 0.3-3.7; and adjusted odds ratio, 1.1; 95% CI,
0.3-3.7). There was a trend for increased 30-day mortality for the EVAR
group in 2005 to 2009 compared with 1998 to 2004 (unadjusted odds
ratio, 1.9; 95% CI, 0.8-4.5; and adjusted odds ratio, 1.7; 95% CI, 0.6-4.6).
Comment: Some patients with rAAA who arrive at the hospital alive
are still going to die despite the use of EVAR for treatment. The report,
however, does suggest that anatomic selection bias for apparent improved
mortality rates with EVAR may not be the explanation for the apparent
beneﬁt of EVAR in the treatment of rAAA. EVAR avoids the physiologic
challenge of an open operation for a patient in potential extremis. However,
if the EVAR patient requires abdominal decompression, there is no differ-
ence in mortality compared with an open operation. Although the authors’
approach to treatment of rAAA requires considerable experience with endo-
vascular techniques and a large array of devices immediately available, the
growing ability and willingness to transfer patients with rAAAs to regional
centers suggests that this approach is likely to gain increasing utilization.Characteristics of Ischemic Brian Lesions After Stenting or
Endarterectomy for Symptomatic Carotid Artery Stenosis: Results
From the International Carotid Stenting Study-Magnetic Resonance
Imaging Substudy
Gensicke H, Zumbrunn T, Jongen LM, and the ICSS-MRI Substudy
Investigators. Stroke 2013;44:80-6.
Conclusion: In patients with symptomatic carotid artery stenosis,
those undergoing carotid endarterectomy (CEA) have fewer periprocedural
lesions on diffusion-weighted (DWI) magnetic resonance imaging (MRI)
than those undergoing carotid artery stenting (CAS). CAS DWI lesions
were smaller and more likely to occur in cortical areas and subadjacent white
matter.Summary: The International Carotid Stenting Study (ICSS) random-
ized patients with symptomatic carotid artery stenosis to treatment with
CEA or CAS. The ICSS-Magnetic Resonance Imaging Substudy of ICSS
compared risk of periprocedural cerebral ischemia on MRI between the
two groups. Initial ﬁndings were that 50% of patients treated with CAS
and 17% of those with CEA had one or more new ischemic lesions on
DWI imaging at a median of 1 day after treatment (Bonati LH et al, Lancet
Neurol 2010;9:353-62). However, this initial study provided only
outcomes on a binary basis. Results were only reported as the presence or
absence of one or more new DWI lesions after treatment. This was reported
independently of the total number of lesions, volume of lesions, and loca-
tion of lesions. The authors postulated that comparing the total number
of lesions per patient would provide more information and might be better
suited to compare the risk of periprocedural embolism between treatments.
In this current analysis of the ICSS-MRI substudy, the authors compared
numbers of new DWI lesions between patients with symptomatic carotid
artery stenosis treated with CAS vs CEA. They also analyzed the relative
prevalence of lesions in various patient subgroups, and in addition,
compared volumes of ischemic lesions and location of ischemic lesions
between treatments. There were 124 patients in the CAS subgroup and
107 in the CEA subgroup of ICSS-MRI. CAS patients had higher lesion
numbers than CEA patients (1 lesion, 15% vs 8%; 2-5 lesions, 19% vs 5%;
>5 lesions, 16% vs 4%). The overall risk ratio for the expected lesion count
with CAS vs CEA was 8.8 (95% conﬁdence interval, 4.4-17.5; P > .0001).
Lesion counts were signiﬁcantly increased among patients with lower blood
pressure at randomization, those with diabetes mellitus, those with stroke as
the qualifying event, in patients with left-sided stenosis, and if patients were
treated at centers routinely using ﬁlter-type protection devices during CAS.
Individual lesions were larger in the CEA group than in the CAS group
(P < .0001). Total lesion volume did not differ signiﬁcantly between treat-
ment groups. Lesions in the CAS group were more likely to occur in cortical
areas and in subjacent white matter supplied by leptomeningeal arteries than
lesions in the CEA group (odds ratio, 4.2; 95% conﬁdence interval,
1.7-10.2; P ¼ .002).
Comment: Previous nonrandomized studies have also reported more
frequent occurrence of periprocedural DWI lesions after CAS compared
with CEA. The current study has similar ﬁndings. The volume of ischemic
brain tissue was similar between the two groups secondary to larger lesions
in the CEA vs CAS patients. Of interest is that the authors found higher
rates of DWI lesions associated with the use of ﬁlter cerebral protection
devices. This suggests use of ﬁlter devices for cerebral protection during
CAS may not be the route to improve periprocedural results with CAS.
Because of higher statistical power, analysis of lesion count may be the
preferred method to compare treatment of atherosclerotic carotid artery
stenosis in DWI-based studies.Volume-Outcome Relationships in Lower Extremity Arterial Bypass
Surgery
Moxey PW, Hofman D, Hinchliffe RJ, et al. Ann Surg 2012;256:1102-7.
Conclusion: There is positive volume-outcome relationship for lower
extremity arterial bypass (LEAB) surgery.
Summary: Previous studies have suggested the relationship between
increased case volume and improved outcomes for abdominal aortic aneu-
rysms (AAA) and carotid endarterectomy (Nazarian SM et al, J Vasc Surg
2008;43:343-50; Young EL et al, J Vasc Surg 2007;46:1287-94). Relation-
ships between volumes of LEAB and favorable outcomes were explored in
a recent meta-analysis suggesting beneﬁcial effects with higher surgical
volumes (Awopetu AI et al, Br J Surg 2010;97:797-803). This analysis,
however, pointed out the paucity of studies in the literature on this subject
and the heterogeneity of the studies included in the meta-analysis. In this
study, the authors sought to quantify volume-outcome relationships for
LEAB surgery over a 5-year period. Outcome measures included revision
of bypass surgery, major amputation, and mortality during the initial admis-
sion and at 1 year postprocedure. Multilevel modeling techniques were
used. The studies analyzed all LEAB procedures performed in England
between 2002 and 2006. For each patient, a Charleston-type risk proﬁle,
including operating hospital annual case volume, was identiﬁed. Quintile
analysis and multilevel multivariate modeling were used to identify potential
volume-outcome relationships and to allow adjustment of results for signif-
icant determinacy of outcome. The authors identiﬁed 27,660 femoral popli-
teal bypasses and 4161 femoral distal bypass procedures. With increasing
volume after popliteal bypass there was a decrease in hospital mortality
from 6.5% to 4.9% (P ¼ .0045) and an odds ratio of 0.98 (95% conﬁdence
interval [CI], 0.929-0.992; P ¼ .014) for every increase of 50 patients per
year. Major amputation decreased from 4.1% to 3.2% (P ¼ .006) in high-
volume hospitals, with a reduction in risk of 0.955 (95% CI, 0.928-
0.983; P ¼ .002) at 1 year. For distal bypass, in-hospital mortality decreased
